MAO inhibitors are among the oldest and most effective antidepressants available, yet they are also among the least prescribed, largely because of a well-known interaction with certain foods that can cause dangerous spikes in blood pressure. That reputation, while grounded in real pharmacology, has become somewhat outdated as food safety standards have improved and newer formulations have reduced the risk. Understanding what these drugs actually do, which foods and medications genuinely pose a threat, and how modern versions differ from the originals can help demystify a class of medications that still has a lot to offer.
What MAO Inhibitors Do
Your brain relies on chemical messengers called monoamines, including serotonin, norepinephrine, and dopamine, to regulate mood, motivation, sleep, and movement. An enzyme called monoamine oxidase (MAO) breaks these messengers down after they have done their job. MAO inhibitors block that enzyme, which lets those chemical messengers linger longer and do more work. The result is a boost in the brain’s signaling capacity, which is why these drugs are useful for conditions where that signaling is impaired.
There are two forms of the enzyme. MAO-A preferentially breaks down serotonin and norepinephrine, the messengers most closely tied to mood. MAO-B preferentially breaks down dopamine, which is central to movement and reward. Some MAO inhibitors block one form selectively; others block both. That distinction shapes which conditions each drug treats and which side effects it carries.
What They Treat
MAO inhibitors are approved and used for two main categories of illness: mood disorders and Parkinson’s disease.
For depression, the older irreversible MAO inhibitors like phenelzine and tranylcypromine are especially valued for patients who haven’t responded to other antidepressants. They have shown particular strength in treatment-resistant depression, atypical depression (marked by oversleeping, overeating, and sensitivity to rejection), and bipolar depression.1PubMed. Current place of monoamine oxidase inhibitors in the treatment of depression These are among the hardest mood presentations to treat, and the fact that MAO inhibitors can reach patients who have failed multiple other medications makes them genuinely irreplaceable for some people.
Social anxiety disorder (social phobia) is another condition where MAO inhibitors have performed well. Phenelzine in particular has strong evidence of efficacy for social phobia, and for some patients it remains the most effective pharmacological option.2European Neuropsychopharmacology. Pharmacological treatment of social phobia: Traditional MAOIs and moclobemide
For Parkinson’s disease, MAO-B inhibitors like selegiline, rasagiline, and the newer safinamide are commonly used either alone in early-stage disease or alongside other Parkinson’s medications in more advanced stages. They help improve both motor symptoms (stiffness, slowness, tremor) and non-motor symptoms (mood changes, fatigue), and they reduce the amount of “off” time when other medications wear off between doses.3PubMed Central. Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson’s Disease: Past, Present, and Future Rasagiline has also shown signs of potentially slowing the progression of Parkinson’s disease itself, not just masking symptoms, though the evidence on that front remains a subject of ongoing study.4PubMed Central. Pharmacology of Rasagiline, a New MAO-B Inhibitor Drug for the Treatment of Parkinson’s Disease with Neuroprotective Potential
The Tyramine Problem and Why Cheese Became Famous
The most talked-about risk with MAO inhibitors is the so-called “cheese effect.” Here is what actually happens. Tyramine is a naturally occurring substance found in aged and fermented foods. Under normal circumstances, MAO in your gut and liver breaks down tyramine before it can do much. But when you take an irreversible MAO inhibitor, that safety net is gone. Unmetabolized tyramine floods into your bloodstream, triggers the release of large amounts of norepinephrine, and can cause a sudden, severe spike in blood pressure. In the worst cases, this hypertensive crisis can lead to heart damage.5PubMed. Myocardial Injury from Tranylcypromine-Induced Hypertensive Crisis Secondary to Excessive Tyramine Intake
The foods traditionally flagged include aged cheeses, cured or smoked meats, fermented soy products like soy sauce and miso, draft beer, sauerkraut, and some pickled items. The common thread is aging, fermentation, or bacterial action, all of which allow tyramine to accumulate.
That said, the dietary danger is probably overstated by the food lists most patients receive. Modern food production and refrigeration have dramatically reduced tyramine levels in many products compared to what was typical decades ago when the warnings were first issued. The tables of tyramine content printed in most guides are imprecise because tyramine concentrations vary widely even within foods of the same category; one batch of cheddar might have several times the tyramine of another.6PubMed Central. The Prescriber’s Guide to the MAOI Diet-Thinking Through Tyramine Troubles When tyramine is eaten as part of a normal meal rather than swallowed as a pure capsule, doses under about 50 mg are unlikely to cause a blood pressure rise that would need medical attention, though some sensitive individuals may react to lower amounts.7Psychopharmacology Institute. Dietary Restriction: What to Tell Patients About Tyramine
None of this means you can ignore the diet on an older MAO inhibitor. It means the real risk comes from consuming large portions of the highest-tyramine foods, not from trace amounts in a slice of pizza. The practical approach is to avoid the genuinely high-risk items (aged cheeses like Stilton or aged Gouda, fermented sausages, concentrated yeast extracts) and to be sensible rather than terrified about everything else.
Drug Interactions That Matter More Than Food
While the food interaction gets most of the attention, drug interactions with MAO inhibitors can be equally or more dangerous and are easier to stumble into accidentally. Two categories of medication are the main concern: drugs that raise blood pressure through stimulating the sympathetic nervous system, and drugs that increase serotonin levels.
In the first category, decongestants containing pseudoephedrine or phenylephrine are the classic offenders. Nasal sprays with oxymetazoline fall into the same group. These are found in common cold and flu remedies sold over the counter, so someone on an MAO inhibitor who grabs a box of cold medicine without checking the label could trigger a hypertensive episode.8PubMed Central. Clinically Relevant Drug Interactions with Monoamine Oxidase Inhibitors
In the second category, the worry is serotonin syndrome, a potentially life-threatening condition caused by too much serotonin activity. The combination of an MAO inhibitor with an SSRI (like fluoxetine or sertraline) is the most widely warned-against pairing, and case reports have documented serotonin syndrome with both MAO-A and MAO-B inhibitors when combined with SSRIs.9PubMed Central. Interaction between Monoamine Oxidase B Inhibitors and Selective Serotonin Reuptake Inhibitors But the risk extends beyond prescription antidepressants. Dextromethorphan, the cough suppressant found in many over-the-counter cough syrups, also boosts serotonin and should be avoided. Even certain antihistamines like chlorpheniramine and brompheniramine carry some serotonergic activity.8PubMed Central. Clinically Relevant Drug Interactions with Monoamine Oxidase Inhibitors
The practical takeaway is straightforward: if you are on any MAO inhibitor, read labels carefully on over-the-counter products, and always tell your pharmacist and every prescriber which medications you take. A seemingly innocent cold remedy or cough syrup can be the trigger.
Common Side Effects Beyond the Headlines
The hypertensive crisis gets the headlines, but the day-to-day side effects of MAO inhibitors are more mundane and in some ways more relevant to the experience of taking them.
Postural hypotension, a drop in blood pressure when you stand up, is actually the most common cardiovascular side effect. It can cause dizziness, lightheadedness, and fainting, especially when getting out of bed or standing up quickly. When simple measures like rising slowly and staying hydrated are not enough, doctors may add salt tablets or a medication called fludrocortisone to help expand blood volume.10PubMed. Blood pressure effects of monoamine oxidase inhibitors–the highs and lows The irony is that the same class of drugs famous for dangerously raising blood pressure in one scenario tends to lower it too much in everyday life.
Weight gain is another concern, though it varies by drug. Phenelzine is the MAO inhibitor most consistently associated with weight gain. Reports of weight gain with isocarboxazid exist but are less common, while tranylcypromine has not been clearly linked to weight gain in the published literature.11PubMed Central. Monoamine oxidase inhibitors and weight gain For patients already struggling with the weight gain caused by other antidepressants, this difference among the MAOIs can factor into which one a prescriber chooses.
Sleep disruption is a less well-known effect. MAO inhibitors, particularly phenelzine, can strongly suppress REM sleep, the stage of sleep associated with dreaming. In some patients, REM sleep is completely eliminated early in treatment, though short REM episodes tend to reappear after several months on the medication.12Nature. Effect of Chronic Phenelzine Treatment on REM Sleep: Report of Three Patients Some people experience this as insomnia or unrefreshing sleep, while others barely notice. The effect on sleep architecture is dramatic on a brain-wave recording, but the subjective experience varies a lot from person to person.
Other common side effects include dry mouth, sexual dysfunction, and occasional muscle twitching. These overlap with the side-effect profiles of other antidepressant classes, so they are rarely the deciding factor in whether to prescribe an MAO inhibitor versus something else.
Newer Formulations That Reduce the Risks
A significant part of the story of MAO inhibitors is the effort to keep their therapeutic power while eliminating the tyramine problem. Two main strategies have emerged, and both have produced drugs that are in clinical use today.
The first is the transdermal selegiline patch (sold as Emsam). Selegiline taken by mouth is primarily a MAO-B inhibitor used for Parkinson’s disease, but when delivered through a skin patch, it inhibits both MAO-A and MAO-B in the brain, making it effective for depression. The clever part is that because the drug bypasses the digestive system, it leaves the MAO in your gut and liver largely intact. That gut MAO continues to break down dietary tyramine as usual. At the lowest effective dose (6 mg per 24 hours), the patch eliminates the need for a tyramine-restricted diet entirely.13PubMed Central. The selegiline transdermal system (emsam): a therapeutic option for the treatment of major depressive disorder At higher doses, some dietary caution is still recommended, but the risk is substantially lower than with oral irreversible MAOIs.14PubMed. Selegiline transdermal system: current awareness and promise
The second strategy is reversible inhibition. The older MAO inhibitors bind permanently to the enzyme, which means once a molecule of MAO is blocked, it stays blocked until your body manufactures a replacement, a process that takes about two weeks. Reversible inhibitors, by contrast, can be displaced from the enzyme by a surge of tyramine. If you eat a tyramine-rich food while taking a reversible MAO-A inhibitor, the tyramine can compete with the drug for the enzyme’s binding site, allowing some tyramine to be broken down normally.
Moclobemide is the main reversible MAO-A inhibitor in clinical use (available in many countries, though not in the United States). In therapeutic doses, moclobemide increases tyramine sensitivity only about a third as much as the old irreversible drugs. Put another way, where phenelzine or tranylcypromine multiply your sensitivity to tyramine by a factor of 10 to 30, moclobemide raises it by a much smaller margin.15PubMed. Relationship between tyramine potentiation and monoamine oxidase (MAO) inhibition: comparison between moclobemide and other MAO inhibitors In a head-to-head trial, moclobemide reduced depression scores comparably to tranylcypromine with no clinically relevant tyramine interaction.16PubMed. Double-blind comparison of moclobemide and tranylcypromine in depression
Safinamide, a reversible MAO-B inhibitor used for Parkinson’s disease, follows the same logic on the MAO-B side. These newer agents have not replaced the older drugs for every patient, but they have expanded the options for people who need MAO inhibition without the full burden of dietary restriction.17Frontiers in Pharmacology. Inhibitors of MAO-A and MAO-B in Psychiatry and Neurology
Why Doctors Rarely Prescribe Them
Despite their proven efficacy, MAO inhibitors have been in steady decline for decades. The arrival of SSRIs in the late 1980s gave prescribers a class of antidepressants that was easier to manage and had no dietary restrictions. Concern about food and drug interactions drove many psychiatrists away from MAOIs, and as fewer doctors prescribed them, fewer trainees learned how to use them. The result is a self-reinforcing cycle: many psychiatrists today have never prescribed an MAO inhibitor and are uncomfortable starting one.18PubMed Central. The role of monoamine oxidase inhibitors in current psychiatric practice
This matters because a meaningful number of patients with depression do not respond to SSRIs or newer antidepressants. For those patients, an MAO inhibitor may be the treatment that actually works. The liberalization of the MAOI diet based on more recent tyramine data, along with the availability of transdermal selegiline and moclobemide, has reduced the practical barriers. But awareness among prescribers has been slow to catch up with the evidence.
Switching To or From an MAO Inhibitor
One of the trickier practical aspects of MAO inhibitors is the washout period required when switching between them and other antidepressants. Because irreversible MAOIs disable the enzyme for weeks, there is a window after stopping the drug when its effects are still active even though you are no longer taking it. Starting a serotonergic antidepressant too soon after stopping an MAOI, or starting an MAOI too soon after stopping an SSRI, can trigger serotonin syndrome.
The standard approach is to gradually taper the first antidepressant, then wait through a washout period before beginning the new one. For most SSRIs, two weeks without the drug is considered adequate before starting an MAOI. Fluoxetine is the exception; because it and its active metabolite remain in the body much longer, a five-week washout is typically recommended. Going the other direction, from an irreversible MAOI to an SSRI, the usual wait is about two weeks to allow the body to regenerate its MAO enzyme supply.19PubMed Central. Switching and stopping antidepressants These waiting periods can be frustrating for patients who are suffering, but the risk of rushing the transition is real.
Tobacco Smoke and MAO Inhibition
An unexpected footnote in MAO research involves cigarette smoke. Smokers consistently show reduced MAO activity in the brain, and for years the mechanism was unclear. Research has identified two compounds in tobacco smoke, norharman and harman, both belonging to a family called beta-carboline alkaloids, that act as potent, competitive, and reversible inhibitors of both MAO-A and MAO-B.20PubMed. Human monoamine oxidase is inhibited by tobacco smoke: beta-carboline alkaloids act as potent and reversible inhibitors
This finding has implications for understanding nicotine addiction. If cigarette smoke partially inhibits MAO, it would raise dopamine and serotonin levels in a way that mimics a mild antidepressant effect, independent of nicotine itself. That may help explain why smoking rates are disproportionately high among people with depression and why quitting smoking is so difficult for that population. The “antidepressant” aspect of smoking is not the nicotine alone; the MAO inhibition from other compounds in the smoke may be a separate, reinforcing mechanism. This does not make smoking beneficial, of course, but it illustrates how deeply the MAO system is woven into mood regulation and addictive behavior.